LAB

+ Watchlist + Portfolio

Standard BioTools Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.67
52-Week Range: $0.63 – $1.72
Market Cap: $253.72M
P/E (TTM): —
EPS (TTM): -0.13
Dividend Yield: —

Advanced Metrics

Price/Book: 0.47
PEG Ratio: —
Return on Equity: -11.18%
Return on Assets: -6.61%
Gross Margin: 50.49%
Operating Margin: -38.94%
Profit Margin: 100.36%
Current Ratio: 9.10
Debt/Equity: 0.05
Total Debt: $28.09M
Free Cash Flow: $176.58M
Revenue Growth: -7.60%
Earnings Growth: —
Enterprise Value: $-184.98M

LAB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$97.95M	$106.34M	$91.01M	$85.33M
Cost of Revenue	$60.90M	$55.89M	$46.13M	$42.79M
Gross Profit	$37.05M	$50.45M	$44.88M	$42.54M
Research & Development	$37.38M	$25.95M	$28.83M	$25.99M
Selling, General & Admin	$102.28M	$87.54M	$103.06M	$109.86M
Operating Expenses	$139.67M	$113.49M	$131.89M	$135.85M
Operating Income	-$102.62M	-$63.04M	-$87.01M	-$93.31M
EBITDA	-$173.57M	-$54.46M	-$70.22M	-$85.70M
Pretax Income	-$192.93M	-$74.20M	-$90.40M	-$96.70M
Income Tax	-$2.83M	$452.00K	$542.00K	-$37.88M
Net Income	-$190.10M	-$74.66M	-$138.88M	-$74.90M
Diluted EPS	-2.43	-0.94	-0.52	-0.20
Diluted Shares	78.31M	79.16M	352.67M	381.62M

LAB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$81.31M	$51.70M	$166.73M	$120.86M
Receivables	$17.28M	$19.66M	$14.74M	$13.43M
Inventory	$21.47M	$20.53M	$20.74M	$19.98M
Current Assets	$208.81M	$158.22M	$375.88M	$454.26M
Total Assets	$390.31M	$323.07M	$612.35M	$567.75M
Current Liabilities	$43.44M	$109.33M	$65.89M	$108.31M
Long-Term Debt	$62.81M	$3.98M	$299.00K	$299.00K
Total Debt	$102.66M	$98.21M	$30.70M	$30.83M
Total Liabilities	$471.78M	$471.12M	$140.62M	$143.46M
Retained Earnings	-$926.10M	-$1.00B	-$1.19B	-$1.26B
Shareholders' Equity	-$81.47M	-$148.05M	$471.72M	$424.29M
Working Capital	$165.37M	$48.89M	$309.99M	$345.96M
Net Debt	—	$11.81M	—	—

LAB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$89.37M	-$43.29M	-$143.45M	-$74.34M
Capital Expenditure	-$3.83M	-$2.83M	-$8.36M	-$8.30M
Free Cash Flow	-$93.19M	-$46.12M	-$151.81M	-$82.65M
Depreciation & Amortisation	$15.03M	$15.18M	$16.86M	$10.98M
Stock-Based Compensation	$14.88M	$13.12M	$31.73M	$29.61M
Investing Cash Flow	-$88.13M	$20.24M	$363.17M	$27.41M
Financing Cash Flow	$230.76M	-$6.81M	-$102.62M	$570.00K
Share Repurchases	-$563.00K	-$5.41M	-$40.49M	$0.00
Net Change in Cash	$53.26M	-$29.86M	$117.10M	-$46.36M

LAB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$20.22M	$21.76M	$19.55M	$23.80M	$21.15M
Cost of Revenue	$9.17M	$11.13M	$10.07M	$12.41M	$9.84M
Gross Profit	$11.05M	$10.63M	$9.48M	$11.38M	$11.31M
Research & Development	$5.44M	$6.22M	$6.36M	$7.97M	$2.12M
Selling, General & Admin	$29.82M	$28.11M	$26.59M	$25.34M	$18.61M
Operating Expenses	$35.26M	$34.33M	$32.95M	$33.31M	$20.72M
Operating Income	-$24.21M	-$23.70M	-$23.47M	-$21.92M	-$9.42M
EBITDA	-$20.04M	-$14.28M	-$31.37M	-$20.73M	-$8.01M
Pretax Income	-$23.49M	-$18.28M	-$32.90M	-$22.03M	-$14.62M
Income Tax	-$119.00K	-$609.00K	-$1.22M	-$35.93M	$11.00K
Net Income	-$26.03M	-$33.46M	-$34.69M	$19.28M	$127.07M
Diluted EPS	-0.07	-0.09	-0.09	0.05	0.33
Diluted Shares	378.23M	380.50M	382.63M	385.05M	388.20M

LAB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$150.88M	$158.62M	$129.42M	$120.86M	$265.77M
Receivables	$35.48M	$14.61M	$13.54M	$13.43M	$41.64M
Inventory	$42.13M	$24.17M	$25.42M	$19.98M	$18.59M
Current Assets	$344.02M	$506.04M	$472.44M	$454.26M	$521.45M
Total Assets	$579.60M	$556.97M	$539.64M	$567.75M	$639.11M
Current Liabilities	$56.24M	$98.02M	$107.97M	$108.31M	$42.20M
Long-Term Debt	$299.00K	$299.00K	$299.00K	$299.00K	$299.00K
Total Debt	$31.53M	$28.62M	$27.39M	$30.83M	$29.49M
Total Liabilities	$125.00M	$132.43M	$139.98M	$143.46M	$77.99M
Retained Earnings	-$1.21B	-$1.25B	-$1.28B	-$1.26B	-$1.13B
Shareholders' Equity	$454.60M	$424.54M	$399.66M	$424.29M	$561.12M
Working Capital	$287.78M	$408.01M	$364.47M	$345.96M	$479.25M

LAB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$30.28M	-$20.67M	-$22.20M	-$1.19M	-$46.60M
Capital Expenditure	-$5.05M	-$1.89M	-$886.00K	-$476.00K	-$570.00K
Free Cash Flow	-$35.34M	-$22.55M	-$23.09M	-$1.67M	-$47.17M
Depreciation & Amortisation	$4.17M	$3.99M	$1.52M	$1.29M	$1.41M
Stock-Based Compensation	$9.01M	$6.39M	$8.47M	$5.74M	$8.82M
Investing Cash Flow	$14.63M	$27.50M	-$6.68M	-$8.04M	$191.09M
Financing Cash Flow	-$46.00K	$108.00K	-$112.00K	$620.00K	-$40.00K
Share Repurchases	$0.00	$0.00	$0.00	$0.00	—
Net Change in Cash	-$15.70M	$6.95M	-$29.00M	-$8.61M	$144.45M

Market Snapshot

About

Standard BioTools Inc. develops and commercializes technologies for life sciences research and clinical diagnostics. The company's platforms enable high-throughput genomics, proteomics, and single-cell analysis applications used in drug discovery, translational research, and precision medicine. Standard BioTools serves academic, government, pharmaceutical, biotechnology, and clinical laboratories with integrated systems and consumables for multi-omics analysis.